Signature Diagnostics, a biotechnology company based in Potsdam , is positioned in oncogenomics and clinical oncology diagnostics. The company is dedicated to the development of novel prognostic gene signatures for predicting outcome and drug response in cancer patients.

Signature Diagnostics believes that patient selection and stratification based on gene signatures will soon become an important component of routine cancer treatment. Signature Diagnostics improves the quality of decision making in cancer treatment and patient care.

The company strives to become European leader in predictive colorectal cancer (CRC) diagnostics.

Signature Diagnostics also supports and improves the clinical development of innovative oncology drugs and drug combinations in collaboration with clinical and pharmaceutical partners.